| Dr Lyle Takahashi, PHARM D | |
|
223 E Betteravia Rd, Santa Maria, CA 93454-7803 | |
| (805) 922-7184 | |
| (805) 922-7184 |
| Full Name | Dr Lyle Takahashi |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 223 E Betteravia Rd, Santa Maria, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083908065 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 37882 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lyle Takahashi, PHARM D 700 Via Vista Verde, Santa Maria, CA 93455-4946 Ph: (805) 938-1224 | Dr Lyle Takahashi, PHARM D 223 E Betteravia Rd, Santa Maria, CA 93454-7803 Ph: (805) 922-7184 |
News Archive
In an article published in the March issue of the Journal of Cardiovascular Pharmacology and Therapeutics, researchers from Florida Atlantic University (FAU) assess the totality of evidence, including strengths and limitations of different types of evidence contributing to the debate about cardiovascular disease (CVD) risks of cyclooxygenase-2 (COX-2) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs).
Women treated for cardiovascular disease at the nation's best- performing hospitals have a 39 percent lower risk-adjusted mortality rate when compared with women at the nation's poorest-performing hospitals, according to the fourth annual HealthGrades Women's Health Outcomes in U.S. Hospitals study.
Critical advances in medicine and environmental protection promise to emerge from a new method for biochemical analysis of fluids developed by an international science team led in part by Arizona State University researchers.
A nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors while decreasing toxicity.
CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company's nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.
› Verified 7 days ago
Peter Aiad, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 830 Sloan Ter, Santa Maria, CA 93455 Phone: 502-751-7290 | |
Nehal Ashour, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2399 S Broadway, Santa Maria, CA 93454 Phone: 805-928-4633 | |
Dr. Jake William Bachino, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 223 E Betteravia Rd, Santa Maria, CA 93454 Phone: 805-922-9904 | |
Dr. Sherilyn Vanosdol, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 633 Lewis Rd, Santa Maria, CA 93455 Phone: 805-705-8123 | |
Daniel Donghyok Ko, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2399 S Broadway, Santa Maria, CA 93454 Phone: 805-928-4633 | |
Claudia Loraine Gretlein, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1504 S Broadway, Santa Maria, CA 93454 Phone: 805-922-1747 Fax: 805-925-6499 | |
Craig Leo Kikuchi, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 S Bradley Rd, Santa Maria, CA 93454 Phone: 805-922-3430 Fax: 805-922-9367 |